Vaccine Modernization Act - HR 5142 - A Win for Everyone
The National Childhood Vaccine Injury Act was enacted in 1986 in response to instability in the vaccine market and unpredictable civil litigation that threatened vaccine supply. Congress created the Vaccine Injury Compensation Program (VICP) as a no-fault system to compensate rare vaccine injuries while protecting manufacturers from destabilizing tort exposure.
The framework was innovative. It balanced public health necessity with individual redress. It stabilized vaccine production. It provided a structured judicial forum for compensation.
But nearly forty years later, the statutory architecture remains largely unchanged.
The pain-and-suffering cap remains frozen at $250,000 — the same figure set in 1986. Adjusted for inflation, that amount bears little resemblance to modern economic realities. Administrative capacity has not kept pace with growth in filings. The number of Special Masters and court staff remains limited relative to current caseload demands.
At the same time, filings have increased.
This increase does not mean vaccines have suddenly become more dangerous. It reflects increased public awareness of the VICP. Media coverage has expanded. Law firms now explain the program openly on their websites. Individuals who previously would not have known that a legal remedy existed are now informed of their options.
More awareness leads to more filings. That is not evidence of a safety crisis. It is evidence of greater transparency.
When a statutory program designed in 1986 operates in a 2026 environment — with modern inflation, expanded vaccine platforms, and increased public scrutiny — modernization is not radical. It is responsible governance.
The Vaccine Injury Compensation Program remains essential. But it must be updated to reflect present-day realities.
Now is the time.
Most Effective Legislation Currently Pending - HR 5142
H.R. 5142, the Vaccine Injury Compensation Modernization Act, proposes practical updates to bring the Vaccine Injury Compensation Program (VICP) in line with modern realities. The Bill has been introduced in Congress in each of the last three sessions of Congress.
Here is what the bill would accomplish in plain English and with no hidden fine print:
Increase the Number of Special Masters
The bill removes the outdated cap of eight Special Masters and requires at least ten, with flexibility to add more as needed. Case filings today are many times higher than they were in the 1990s, and adjudicative capacity has not kept pace. This reform allows the court to process claims more efficiently and reduce backlog.
Raise Compensation Caps and Tie Them to Inflation
The bill increases the statutory cap for pain and suffering and vaccine-related death to $600,000 beginning in 2026. It also indexes the cap to inflation going forward so that compensation does not lose value over time. This ensures that the program reflects modern cost-of-living realities rather than 1986 economics.
Extend the Statute of Limitations
The filing window for injury claims would increase from three years. This recognizes that some vaccine-related injuries take time to diagnose and properly attribute.
Add COVID-19 Vaccines to the VICP
The bill directs HHS to add COVID-19 vaccines to the Vaccine Injury Table and identifies several injuries that must be included. It also creates a path for individuals whose claims were previously filed or denied under the Countermeasures Injury Compensation Program (CICP) to seek relief within the VICP framework.
Preserve Liability Protections
Importantly, the bill preserves existing PREP Act liability protections. Expanding compensation does not remove manufacturer protections; it aligns them with a structured federal forum.
Expand and Modernize the Excise Tax
The legislation increases the per-dose excise tax from $0.75 (implemented in 1986) and ties future adjustments to inflation. It also expands the list of covered vaccines to reflect the modern immunization landscape. This strengthens the Vaccine Injury Compensation Trust Fund without relying on taxpayer dollars.
Improve Budget Transparency
The bill requires forward-looking budget planning to ensure adequate staffing and administrative resources for both the VICP and CICP.
Why many of the improvements would increase the day to day function of the VICP, there are also improvements in the manner in which vaccines are added to the VICP, excise tax is increased or special masters are increased automatically without the need of major Congressional legislation to enact simply, routine and common sense improvements to ebb and flow with the current trend of case filings.
1. Expanding Coverage Helps Injured Individuals — and That Cannot Be a Bad Thing
The purpose of the Vaccine Injury Compensation Program is to compensate individuals who suffer rare but real vaccine-related injuries in a predictable, structured forum.
Today, VICP coverage largely tracks vaccines included on the CDC’s childhood immunization schedule and certain vaccines recommended during pregnancy. That framework made sense when the Act was passed in 1986 and the focus was primarily on stabilizing the pediatric vaccine market.
But the vaccine landscape in 2026 looks very different.
Many widely administered adult vaccines — including certain pneumococcal vaccines and shingles vaccines — are not covered under the VICP, despite being routinely administered to millions of Americans. COVID-19 vaccines, among the most widely distributed vaccines in modern history, remain outside the VICP entirely.
This creates an inconsistency.
If a vaccine is widely recommended, widely administered, and integral to public health strategy, there should be a predictable and uniform compensation mechanism available in the rare event of serious injury.
Expanding VICP eligibility to include additional routinely recommended vaccines does not weaken vaccination policy. It strengthens it.
A compensation system that reflects the modern vaccine landscape increases public trust. It reduces confusion about where claims must be filed. It prevents injured individuals from being pushed into less structured or less transparent programs. And it aligns liability protections with a comprehensive compensation framework.
Expanding coverage ensures that individuals are not left without a remedy simply because a vaccine was added to the market decades after the Act was written or deployed under emergency authority.
There is no rational policy argument against providing fair compensation to legitimately injured individuals in a structured forum — especially when that forum is self-funded and designed to preserve vaccine stability.
Modernizing coverage is not a retreat from vaccination. It is a reinforcement of the system that sustains it.
2. Broader VICP Coverage Strengthens Liability Protection for Manufacturers
Modernizing the Vaccine Injury Compensation Program does not just help injured individuals — it also strengthens stability for vaccine manufacturers.
When vaccines are included within the VICP framework, design defect claims are preempted under Supreme Court precedent (Bruesewitz v. Wyeth). That preemption protects manufacturers from unpredictable jury verdicts and the variability of civil tort litigation.
At present, certain vaccines administered widely in adult populations remain outside the VICP structure. Manufacturers of those products face ongoing civil litigation exposure — including litigation involving Gardasil and Zostavax.
Expanding VICP coverage would:
· Reduce civil litigation uncertainty for manufacturers
· Consolidate claims into a structured, judicial compensation forum such as the VICP
· Limit exposure to design defect claims in civil court
· Reduce uncertainty about future civil litigation exposure
In practical terms, modernization aligns structured compensation with structured liability protection.
This alignment benefits everyone.
A modernized VICP would likely result in swifter and more equitable compensation, reducing incentives for petitioners to opt out and pursue civil litigation. When injured individuals have confidence in the fairness of vaccine court, opt-outs decrease. Predictability increases. Litigation volatility declines.
Manufacturers benefit from a stable liability framework that encourages long-term planning and continued innovation. Vaccines are complex biological products that require significant research, development, and capital investment. A predictable compensation and liability system supports continued advancement in vaccine science.
The biotechnology industry, including many vaccine manufacturers represented within BIO, has a direct interest in strengthening and stabilizing the VICP framework. Legislative reform such as H.R. 5142 offers an opportunity to modernize liability protections while improving compensation fairness.
This is not a partisan issue. It is a structural one.
A coordinated effort among policymakers, manufacturers, and stakeholders to modernize the Vaccine Act would reinforce both public health and industry stability.
Now is a logical time for collaboration.
3. Raising the Pain and Suffering Cap Is Long Overdue
The statutory cap for pain and suffering under the Vaccine Act remains $250,000 — a figure set in 1986.
In a structured no-fault compensation system, caps can serve a legitimate purpose. They create predictability. They allow policymakers to balance compensation with fiscal sustainability. They help preserve stability for manufacturers and the vaccine supply chain.
But caps must be reasonable. And they must reflect economic reality.
Adjusted for inflation, the 1986 cap would be significantly higher today. Yet the statute has not been updated to account for nearly four decades of rising costs of living, medical care, and long-term support needs.
Increasing the cap to reflect 2026 realities — for example, to $600,000 — does not mean that every claimant would receive that amount. Most claims would continue to resolve below the statutory maximum.
What it does mean is that catastrophically injured individuals — those who are wheelchair-bound, unable to walk, unable to live independently, or who suffer profound neurological injury — would not be confined to an archaic compensation ceiling that fails to account for modern economic conditions.
A cap tied to inflation is not radical. It is responsible governance.
Fair compensation reduces incentives for injured individuals to opt out and pursue civil litigation. When vaccine court produces outcomes that reflect present-day realities, confidence in the system increases.
Better outcomes within the VICP mean fewer plaintiffs seeking alternatives in state and federal courts.
That stability benefits both injured individuals and manufacturers — and strengthens the long-term integrity of the program.
4. More Special Masters Means Faster Results — For Everyone
The Vaccine Act of 1986 limits the Office of Special Masters to no more than eight Special Masters. That statutory cap has remained unchanged for nearly four decades.
The workload has not.
From 1992 to 2001, the VICP averaged approximately 170 petitions filed per year. Over the past ten years, filings have averaged roughly 1,200 petitions annually — a more than sevenfold increase in caseload.
The number of Special Masters, however, has remained capped at eight.
That mismatch has predictable consequences. When filings increase but adjudicative capacity does not, processing times lengthen. Entitlement decisions take longer. Damages proceedings are delayed. Resolution slows for both injured petitioners and manufacturers.
The need for additional Special Masters is not speculative — it is structural.
Allowing the U.S. Court of Federal Claims to appoint three or four additional Special Masters would meaningfully reduce backlog and restore reasonable processing timelines. This is not a dramatic expansion of government. It is a targeted adjustment to reflect modern caseload realities.
From a fiscal perspective, this is a modest undertaking. Special Masters are salaried judicial officers within the federal judiciary. Even accounting for support staff and administrative costs, adding several additional Special Masters would likely amount to only a few million dollars annually, which is paid for by the Vaccine Trust Fund, not taxpayer monies from the general tax budget.
In the context of the overall federal budget, that cost is minimal. It is particularly modest when compared to the broader economic consequences of delayed adjudication, prolonged uncertainty, and potential increases in civil opt-outs.
Faster resolution benefits everyone:
· Injured individuals receive answers sooner.
· Manufacturers face reduced litigation uncertainty.
· Opt-out incentives decline.
· The integrity of the compensation system strengthens.
The VICP is a self-funded compensation program. Increasing Special Master capacity does not alter the Vaccine Injury Compensation Trust Fund. It simply ensures that the judicial structure administering the program can keep pace with modern demand.
When caseloads increase sevenfold and staffing remains frozen in 1986, reform is not expansion — it is maintenance.
5. The Excise Tax Has Not Changed in 40 Years
The Vaccine Injury Compensation Trust Fund is not taxpayer funded.
It is funded through a $0.75 excise tax per vaccine component — a figure that has remained unchanged since the program’s inception in the late 1980s.
That number has not been adjusted for inflation in nearly forty years.
In 1986, seventy-five cents carried meaningfully different economic weight than it does today. Adjusted for inflation, the real value of that contribution has declined substantially over time.
Increasing the excise tax modestly would:
· Strengthen the long-term solvency of the Trust Fund
· Support higher, inflation-adjusted compensation caps
· Provide resources for administrative modernization
· Ensure the program remains stable as vaccine platforms expand
This reform would not burden taxpayers. The Trust Fund is financed by vaccine manufacturers through the per-dose excise tax. When claims are paid, they are paid from that fund — not from general revenue.
Manufacturers benefit from significant liability protections under the Vaccine Act, including preemption of most design defect claims and consolidation of litigation into a structured compensation forum. A modest increase in the excise tax simply aligns funding levels with the modern liability protections and economic realities that exist today.
The goal is not to penalize manufacturers. It is to ensure that the compensation system remains robust, solvent, and capable of fairly compensating those who suffer rare but serious vaccine-related injuries.
When a compensation system has functioned for forty years without adjusting its funding mechanism for inflation or growth in vaccine platforms, updating that mechanism is not radical. It is responsible stewardship.
The Trust Fund exists for one purpose: to compensate injured individuals fairly and efficiently. Modernizing the excise tax ensures that it can continue to do so.
6. Fiscal Impact: Fully Funded by the Vaccine Trust Fund — Not Taxpayers
The Vaccine Injury Compensation Program is a self-funded program. When claims are paid, they are paid from the Vaccine Injury Compensation Trust Fund — not from general taxpayer revenue. The Trust Fund is financed through a per-dose excise tax on covered vaccines. It does not rely on annual congressional appropriations to fund compensation awards.
Importantly, the salaries, operating budget, and administrative expenses of the Office of Special Masters are also paid from the Vaccine Injury Compensation Trust Fund.
That means modernization — including increasing compensation caps, expanding vaccine coverage, adjusting excise tax rates, or adding additional Special Masters — does not impose a burden on taxpayers.
The compensation mechanism is structurally independent from general federal revenue.
Under the current statute, the number of Special Masters is capped at eight — a number set in 1986, when annual filings averaged fewer than 200 cases per year. Today, filings average approximately 1,200 petitions annually.
Allowing the Court to appoint additional Special Masters to match modern caseload levels would not draw from taxpayer funds. Their salaries and support costs would be paid from the Vaccine Injury Compensation Trust Fund — the same fund financed by vaccine manufacturer per-dose contributions.
In other words:
Compensation awards are paid by the Trust Fund.
Administrative costs are paid by the Trust Fund.
Judicial staffing increases would be paid by the Trust Fund.
There is no general taxpayer implication embedded in these reforms.
The return on strengthening staffing capacity would be substantial:
Faster case resolution
Reduced backlog
Lower litigation uncertainty
Fewer civil opt-outs
Increased confidence in the compensation system
A properly staffed VICP benefits injured individuals, manufacturers, healthcare providers, and the broader public health system.
For a program that underpins national vaccine stability, ensuring that it is adequately resourced through its own self-funded trust structure is not expansion — it is responsible stewardship.
Modernization strengthens a self-contained system without shifting costs to the public.
7. Reform Reduces Litigation Risk and Increases Public Confidence
A properly modernized Vaccine Injury Compensation Program does more than update numbers on a statute. It strengthens the entire compensation structure.
A modernized VICP would:
· Encourage injured individuals to remain in vaccine court
· Reduce civil opt-outs
· Strengthen manufacturer liability protections
· Improve efficiency and predictability
· Reinforce public trust in vaccine policy
The key factor is not simply compensation levels — it is efficiency.
When the system is properly staffed, cases are heard promptly, and decisions are issued without unnecessary delay, petitioners feel heard. They feel that the system is responsive. They feel that the process is legitimate.
When resolution is swift and fair, fewer petitioners feel compelled to opt out and pursue civil litigation after exhausting the VICP process.
Reduced opt-outs benefit manufacturers directly. Civil litigation is expensive, unpredictable, and public. A structured, efficient federal compensation system reduces exposure to jury variability and prolonged discovery.
For the biotechnology industry and organizations such as BIO, modernization should be viewed as risk management. A stable, adequately staffed, and transparent compensation program reduces long-term litigation volatility and enhances public confidence in vaccine infrastructure.
Efficiency is not just administrative housekeeping — it is structural reinforcement.
When injured individuals believe the compensation system is fair, current, and capable of delivering timely results, they are more likely to remain within it. When manufacturers operate within a predictable liability framework, they can focus on innovation rather than litigation strategy.
Modernization aligns incentives across stakeholders.
An efficient VICP strengthens both compensation and vaccine stability. That alignment should motivate broad support for reform.
Bottom Line: HR 5142 Is a Common-Sense Modernization of the Vaccine Injury Compensation Program
The Vaccine Injury Compensation Program was created in 1986 to stabilize the vaccine market and fairly compensate individuals who suffer rare but serious vaccine-related injuries.
Nearly forty years later, the structure remains largely unchanged.
HR 5142 represents a series of practical, common-sense upgrades to ensure that the program reflects 2026 realities:
Adjusting compensation caps to account for decades of inflation
Expanding vaccine coverage to reflect the modern immunization landscape
Increasing Special Master capacity to reduce backlog and improve efficiency
Strengthening the Vaccine Injury Compensation Trust Fund through modest excise tax adjustments
These reforms are not radical. They are maintenance improvements.
They help injured individuals receive fair compensation.
They strengthen liability protections for manufacturers.
They reduce civil litigation volatility.
They improve administrative efficiency.
They increase public trust in public health policy, vaccines and the justice system.
Reform should be endorsed by:
Vaccine injury practitioners who see firsthand where the system strains
The biotechnology industry and vaccine manufacturers who benefit from predictable liability protection
The medical community that relies on stable vaccine infrastructure
And the Department of Health and Human Services, which administers and defends the program
HHS defends vaccine injury claims, but Congress did not task it with defending every case at all costs. The statutory purpose of the Vaccine Act is to provide compensation where the evidentiary standard is met while preserving vaccine stability.
That dual responsibility requires balance — not obstruction.
Common-sense modernization strengthens the program without undermining its foundation.
The VICP remains one of the most important public health liability frameworks in the country. Updating it is not a partisan issue. It is responsible governance.
HR 5142 is a practical step toward ensuring that the Vaccine Injury Compensation Program remains fair, efficient, and structurally sound for the next generation.